Core Viewpoint - The recent strategic partnership between 联康生物科技集团 and 科兴生物制药 is aimed at expanding the commercialization of a novel osteoporosis treatment across six countries in the Middle East and Latin America [1] Group 1: Shareholder Activity - On September 23, shareholders of 联康生物科技集团 deposited shares worth HKD 113 million into HSBC Hong Kong, representing 12.33% of the total shareholding [1] Group 2: Strategic Partnership - 联康生物科技集团's wholly-owned subsidiary, 北京博康健基因科技有限公司, has signed a strategic cooperation agreement with 科兴生物制药股份有限公司 [1] - The agreement grants 科兴制药 exclusive commercialization rights for the innovative osteoporosis treatment 博固泰® in six countries: Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico [1]

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug Bogu Tai® in six countries [1][2] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai® in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai® has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The partnership is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Beijing Bokan Gene Technology Co., Ltd. and Sinovac Biotech Ltd. for the exclusive commercialization of the osteoporosis treatment drug Bogu Tai® in six countries, which presents significant market opportunities [1] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures, addressing unmet medical needs in the market [1] - The target market for this partnership includes over 10 million osteoporosis patients with a market size of nearly $1.5 billion, indicating a substantial opportunity for growth [1] Group 2 - Sinovac Biotech is a leading innovative multinational biopharmaceutical company with operations in multiple countries and regions, which has achieved market access and sales in dozens of global markets [2] - The board of Sinovac Biotech views this collaboration as a key milestone in its global expansion strategy, reinforcing its position in the osteoporosis treatment market and providing long-term value for shareholders [2] - Since its launch in China in March 2024, Bogu Tai® has seen significant success, with revenue growth of 248.9% year-on-year in the first half of 2025, indicating strong market demand and performance [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 布 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 自願性公佈 科 興 製 藥（ 股 票 代 碼 ： 688136.SH ）是 一 家 領 先 的 創 新 型 跨 國 生 物 製 藥 企 業 ， 其 設 立 並 運 營 6 家 海 外 子 公 司和 辦 事 處 ， 已 通 過 歐盟 、 巴 西 、 菲 律 賓 、 印度 尼 西 亞 等 全球幾十個國家和地區的市場准入並實現銷售。 聯康生物科技集團通過戰略合作拓展博固泰®全球市場 香港，二零二五年九月十二日 — 聯康生物科技集團有限公司（「本公司」），連同其 附屬公司統稱（「本集團」）董事會（「董事會」）欣然宣佈，其全資子公司北京博康健基 因科技有限公司（「北京博康健」）與科興生 ...